{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 52,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines the clinical trial methodology, specifically the randomization and treatment arms for advanced endometrial cancer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/35",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.82,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study design flow chart showing patient eligibility, randomization, and treatment arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9822fe8f-4ad3-4015-8be4-1c3e2b26b45c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "PFS = progression-free survival; MMR = mismatch repair; R = randomisation; PC = paclitaxel/carboplatin; CTx = chemotherapy; PD = progressive disease; OS = overall survival.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9c8dcec-a2bb-473c-9aea-5afcfed74f14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.38,
        "y": 0.78
      },
      "kind": "subtitle",
      "text": "Only patients with no evidence of PD allowed to continue on maintenance therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "038c1659-b101-439a-b1e4-86a03e5a1fd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Imfinzi plus Lynparza and Imfinzi alone significantly improved PFS when added to chemotherapy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72b3c98c-653c-4e43-997e-d6d5cbbb2ad5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "DUO-E Phase III in advanced endometrial cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31ea9b6a-b4fe-4cfa-9911-bfc540ba151f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "f8661725-f477-45c3-a904-0e5af5473c03",
      "evidence": "The slide depicts a standard randomized controlled trial (RCT) study design flow.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 52,
      "from": 26,
      "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}